Cognition Therapeutics: Upcoming Investor Conferences Insights
Overview of Cognition Therapeutics
Cognition Therapeutics, Inc. (NASDAQ: CGTX) is a clinical-stage biopharmaceutical company that is at the forefront of developing innovative therapies aimed at treating neurodegenerative disorders. Focused on diseases like Alzheimer’s, Dementia with Lewy Bodies, and Dry Age-related Macular Degeneration, the company utilizes first-in-class small molecule therapeutics. Their leading candidate, CT1812, has shown promising results in clinical trials, paving the way for better treatment options for patients.
Upcoming Investor Conferences
Cognition Therapeutics is gearing up to participate in two significant investor conferences this September. These events are vital for the company to connect with investors, share updates on their clinical programs, and discuss future plans.
Chardan Capital Markets Leadership Call
The first event on the agenda is the Chardan Capital Markets Leadership Call, scheduled for September 5, 2024, at 11:00 AM ET. This virtual call will provide participants with insights into the company’s recent progress and strategic initiatives. Interested individuals can register by emailing corpaccess@chardan.com.
H.C. Wainwright 26th Annual Global Investment Conference
The second conference is the prestigious H.C. Wainwright 26th Annual Global Investment Conference, taking place from September 9-11, 2024. A webcast of the event will be available starting on September 9th at 7:00 AM ET, allowing broader access for investors eager to learn more about Cognition's advancements.
Recent Developments in Alzheimer's Research
CEO Lisa Ricciardi emphasized the importance of these events, stating that the recent results from the Phase 2 SHINE study indicated that their orally delivered CT1812 slowed the progression of mild-to-moderate Alzheimer’s disease after just six months of treatment. This breakthrough treatment represents hope for patients and families affected by this debilitating condition.
Engaging with Investors
These conferences are essential platforms for Cognition Therapeutics to keep investors informed and engaged as they work diligently towards enhancing their clinical programs. With the imminent readout of the SHIMMER Phase 2 study expected by the end of the year, these discussions will be critical in shaping the company’s future trajectory.
Contact Information for Cognition Therapeutics
For more inquiries, investors and interested parties can reach out through the following lines:
Cognition Therapeutics, Inc.
Email: info@cogrx.com
Media Contact:
Casey McDonald
Tiberend Strategic Advisors, Inc.
Email: cmcdonald@tiberend.com
Investor Contact:
Mike Moyer
LifeSci Advisors
Email: mmoyer@lifesciadvisors.com
Frequently Asked Questions
What is Cognition Therapeutics known for?
Cognition Therapeutics is focused on developing first-in-class therapies for neurodegenerative diseases, particularly Alzheimer’s.
What are the key events Cognition Therapeutics is participating in?
The company is participating in the Chardan Capital Markets Leadership Call and the H.C. Wainwright Annual Global Investment Conference.
What recent advancements has Cognition Therapeutics made?
The Phase 2 SHINE study indicated that CT1812 can slow the progression of Alzheimer’s disease.
How can I attend Cognition Therapeutics’ investor conferences?
Interested participants can register via email for the events, such as the Chardan Capital Markets Leadership Call.
Who can I contact for more information?
For inquiries, you can reach out to Cognition Therapeutics through the email addresses provided above, depending on whether you're an investor or media representative.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Coloplast A/S Share Trading Insights for Board and Executives
- Global Cash Handling Device Market Growth Insights
- Plumas Bank Unveils 2024 Corporate Citizenship Insights
- GeoVax Labs, Inc. Announces Upcoming Investor Events!
- Kronos Bio to Showcase Research at Key Medical Conferences
- NMI Holdings, Inc. Investor Day Scheduled for November 2024
- Robinhood to Share Insights at Goldman Sachs Conference
- Avenue Therapeutics Announces Participation in Investor Conferences
- Y-mAbs Therapeutics to Present at Key Investor Conferences
- Schwab Insights: Boost Your Retirement Savings Effectively
- Market Insights: Futures Dip Amid Nvidia and Tesla News
- Senti Bio Hosts Key Investor Conferences This Fall
- Enviri Corporation Prepares for Key Investor Conferences
- Processa Pharmaceuticals and Upcoming Industry Conferences
- Compass Therapeutics Engages Investors at Upcoming Events
- Earnings Reports Tuesday: Zscaler, Gitlab, Healthequity Insights
- Key Manufacturing PMI and ISM Data for Market Insights
- Kevin Guest's Insights on the Power of Entrepreneurs Today
- Navigating Risks for Bullish Investors this September
- Investors Weigh AI Boom Amidst Market Volatility
- Tourmaline Bio Announces Participation in Investor Conferences
- Amicus Therapeutics to Showcase at Investor Conferences This Fall
- Opthea's Upcoming Presentations at Investment Conferences
- Abeona Therapeutics Engages Investors at Upcoming Conferences
- Arbutus Biopharma's Upcoming Conferences and Innovations
Recent Articles
- Weatherford Strengthens Digital Portfolio with Datagration Deal
- PTC Welcomes Rob Bernshteyn to the Board of Directors
- Worksport's Dealer Initiative Drives Strong Sales Growth
- UMMC Partners with Fiducius for Financial Wellness Initiative
- Keros Therapeutics Progresses in Phase 2 TROPOS Trial for PAH
- India's August Market Overview: Defensive Sectors Thrive
- Is Norwegian or Carnival Cruise Line Stock the Better Buy?
- Green Bonds Market Expected to Reach $960 Billion by 2033
- Why T. Rowe Price Stands Out as a Solid Investment Today
- 23andMe Showcases Breakthroughs in Clinical Immuno-oncology
- Liberian President Boakai Inspires at National Black Business Conference
- Elevation Oncology Highlights Upcoming H.C. Wainwright Conference
- Video Conferencing Solutions Market to Hit $49.7 Billion by 2032
- Vaxcyte's VAX-31 Vaccine Shows Promising Phase 1/2 Study Results
- Emission Monitoring Systems Market Projected Growth to $10.7B
- Vow ASA Insights: Recent Insider Trading Activity Reported
- Find Comfort and Assurance This Fall at Gate of Heaven
- REMSleep Secures Patent Approval for Nasal Ventilation System
- September Stock Market Challenges: Preparing Your Portfolio
- Essential Tips for Baby Safety Month to Prepare for Parenthood
- Industrial 3D Printing Market Projected to Reach $88 Billion
- Plant-Based Meat Market Growth Expected to Reach $31.7 Billion
- China and South Africa Collaborate for Enhanced Trade Growth
- Suominen Corporation's Nomination Board Composition Update
- China-Africa Cooperation: Paving the Way for Modernization